| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLEC3B |
| Uniprot No | P05452 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-202aa |
| 氨基酸序列 | EPPTQKPKKIVNAKKDVVNTKMFEELKSRLDTLAQEVALLKEQQALQTVC LKGTKVHMKCFLAFTQTKTFHEASEDCISRGGTLSTPQTGSENDALYEYL RQSVGNEAEIWLGLNDMAAEGTWVDMTGARIAYKNWETEITAQPDGGKTE NCAVLSGAANGKWFDKRCRDQLPYICQFGIVVDHHHHHH |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLEC3B(Tetranectin)重组蛋白的3篇参考文献示例(注：文献信息为虚构示例，实际文献需通过数据库验证):
---
1. **标题**: *"Recombinant human Tetranectin inhibits tumor metastasis via modulation of plasminogen activation system"*
**作者**: Olsen A, et al.
**摘要**: 研究利用大肠杆菌表达系统成功制备重组人CLEC3B蛋白，证明其通过结合纤溶酶原并增强其激活，显著抑制小鼠模型中肿瘤细胞的转移能力，提示其在癌症治疗中的潜在应用。
2. **标题**: *"Expression and purification of biologically active CLEC3B in Pichia pastoris"*
**作者**: Smith J, et al.
**摘要**: 报道在毕赤酵母系统中高效表达具有生物活性的CLEC3B重组蛋白，通过亲和层析纯化后验证其与钙离子依赖性配体结合能力，为后续功能研究提供可靠蛋白来源。
3. **标题**: *"Tetranectin as a prognostic biomarker: Recombinant CLEC3B suppresses osteosarcoma cell invasion in vitro"*
**作者**: Zhang L, et al.
**摘要**: 通过体外实验证明重组CLEC3B蛋白可下调MMP-9表达，抑制骨肉瘤细胞侵袭，临床数据分析显示CLEC3B低表达与患者不良预后相关，提示其双重生物学意义。
---
**建议**：实际研究中可通过PubMed、Web of Science等平台以关键词“CLEC3B recombinant”、“Tetranectin expression”检索最新文献，重点关注其结构解析、疾病机制及治疗应用方向。
**Background of CLEC3B Recombinant Protein**
CLEC3B (C-Type Lectin Domain Family 3 Member B), also known as tetranectin, is a secreted protein encoded by the *CLEC3B* gene in humans. It belongs to the C-type lectin superfamily, characterized by calcium-dependent carbohydrate-binding domains. CLEC3B is primarily recognized for its role in regulating extracellular matrix (ECM) remodeling, cell adhesion, and tissue repair. Structurally, it forms homotrimers and interacts with plasminogen, enhancing its activation to plasmin, a key enzyme in fibrinolysis and proteolytic processes. This interaction underscores CLEC3B's involvement in tissue homeostasis, bone development, and wound healing.
CLEC3B has been implicated in various pathological conditions. Reduced expression is associated with cancer progression, particularly in osteosarcoma, breast cancer, and glioblastoma, where it may suppress metastasis by modulating ECM degradation. Conversely, elevated levels are linked to neurodegenerative disorders like Alzheimer’s disease, suggesting a dual role in health and disease.
Recombinant CLEC3B protein is produced using expression systems (e.g., *E. coli* or mammalian cells*) to ensure proper folding and post-translational modifications. It serves as a vital tool for studying CLEC3B's molecular mechanisms, ligand interactions, and therapeutic potential. Researchers utilize it to explore its diagnostic utility as a biomarker or its therapeutic application in regenerative medicine and cancer treatment. Recent studies also highlight its involvement in bone morphogenetic protein (BMP) signaling and neuronal repair, expanding its relevance in diverse biomedical fields.
In summary, CLEC3B recombinant protein bridges fundamental research and clinical applications, offering insights into ECM dynamics, disease pathways, and novel therapeutic strategies.
×
